Aytu Biopharma Stock Forecast, Price & News

Aytu Biopharma (NASDAQ:AYTU) Frequently Asked Questions

Is Aytu Biopharma a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aytu Biopharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aytu Biopharma stock.
View analyst ratings for Aytu Biopharma or view top-rated stocks.

How has Aytu Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Aytu Biopharma's stock was trading at $1.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AYTU shares have increased by 33.3% and is now trading at $1.80.
View which stocks have been most impacted by COVID-19.

Are investors shorting Aytu Biopharma?

Aytu Biopharma saw a increase in short interest in October. As of October 29th, there was short interest totaling 1,930,000 shares, an increase of 31.3% from the October 14th total of 1,470,000 shares. Based on an average daily volume of 346,800 shares, the days-to-cover ratio is currently 5.6 days. Currently, 7.8% of the shares of the stock are short sold.
View Aytu Biopharma's Short Interest.

When is Aytu Biopharma's next earnings date?

Aytu Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Aytu Biopharma.

How were Aytu Biopharma's earnings last quarter?

Aytu Biopharma, Inc. (NASDAQ:AYTU) issued its quarterly earnings results on Monday, November, 15th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.60. Aytu Biopharma had a negative trailing twelve-month return on equity of 26.42% and a negative net margin of 110.57%. During the same period in the previous year, the business earned ($0.40) EPS.
View Aytu Biopharma's earnings history.

When did Aytu Biopharma's stock split? How did Aytu Biopharma's stock split work?

Aytu Biopharma shares reverse split on the morning of Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of Aytu Biopharma stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for AYTU?

2 equities research analysts have issued 1 year target prices for Aytu Biopharma's stock. Their forecasts range from $11.00 to $14.50. On average, they anticipate Aytu Biopharma's share price to reach $12.75 in the next year. This suggests a possible upside of 608.3% from the stock's current price.
View analysts' price targets for Aytu Biopharma or view top-rated stocks among Wall Street analysts.

Who are Aytu Biopharma's key executives?

Aytu Biopharma's management team includes the following people:

• Joshua R. Disbrow, Chairman & Chief Executive Officer
• Jarrett T. Disbrow, Executive Vice President-Corporate Development
• Richard I. Eisenstadt, Chief Financial Officer, Secretary & Treasurer
• Russell Lee McMahen, Senior Vice President-Research & Development
• Suzane Kennedy, VP-Regulatory Affairs & Quality Assurance

Who are some of Aytu Biopharma's key competitors?

Some companies that are related to Aytu Biopharma include CM Life Sciences III (CMLT), Vincerx Pharma (VINC), DURECT (DRRX), Impel NeuroPharma (IMPL), Wave Life Sciences (WVE), Avalo Therapeutics (AVTX), Immunome (IMNM), Paratek Pharmaceuticals (PRTK), AVEO Pharmaceuticals (AVEO), TherapeuticsMD (TXMD), Aquestive Therapeutics (AQST), Ardelyx (ARDX), Sensei Biotherapeutics (SNSE), Frequency Therapeutics (FREQ) and Terns Pharmaceuticals (TERN).
View all of AYTU's competitors.

What other stocks do shareholders of Aytu Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu Biopharma investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), ADMA Biologics (ADMA), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), iBio (IBIO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO) and SCYNEXIS (SCYX).

What is Aytu Biopharma's stock symbol?

Aytu Biopharma trades on the NASDAQ under the ticker symbol "AYTU."

Who are Aytu Biopharma's major shareholders?

Aytu Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.40%), BlackRock Inc. (1.81%), Morgan Stanley (1.37%), Millennium Management LLC (1.31%), Geode Capital Management LLC (0.93%) and Commonwealth Equity Services LLC (0.39%). Company insiders that own Aytu Biopharma stock include Armistice Capital Master Fund, Armistice Capital, Llc and Joshua R Disbrow.
View institutional ownership trends for Aytu Biopharma.

Which institutional investors are selling Aytu Biopharma stock?

AYTU stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Citadel Advisors LLC, Schonfeld Strategic Advisors LLC, and Bank of New York Mellon Corp.
View insider buying and selling activity for Aytu Biopharma or view top insider-selling stocks.

Which institutional investors are buying Aytu Biopharma stock?

AYTU stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Renaissance Technologies LLC, Commonwealth Equity Services LLC, Geode Capital Management LLC, Goldman Sachs Group Inc., BlackRock Inc., and Creative Planning. Company insiders that have bought Aytu Biopharma stock in the last two years include Armistice Capital Master Fund, Armistice Capital, Llc, and Joshua R Disbrow.
View insider buying and selling activity for Aytu Biopharma or or view top insider-buying stocks.

How do I buy shares of Aytu Biopharma?

Shares of AYTU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aytu Biopharma's stock price today?

One share of AYTU stock can currently be purchased for approximately $1.80.

How much money does Aytu Biopharma make?

Aytu Biopharma has a market capitalization of $50.67 million and generates $65.63 million in revenue each year. The company earns $-58.29 million in net income (profit) each year or ($4.03) on an earnings per share basis.

How many employees does Aytu Biopharma have?

Aytu Biopharma employs 75 workers across the globe.

What is Aytu Biopharma's official website?

The official website for Aytu Biopharma is aytubio.com.

Where are Aytu Biopharma's headquarters?

Aytu Biopharma is headquartered at 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112.

How can I contact Aytu Biopharma?

Aytu Biopharma's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company can be reached via phone at (720) 437-6580 or via email at [email protected].